Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Covington
Boehringer Ingelheim
Merck
Citi
Deloitte
Julphar
Chubb
Dow
Cipla

Generated: October 24, 2017

DrugPatentWatch Database Preview

Gadofosveset trisodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for gadofosveset trisodium and what is the scope of gadofosveset trisodium freedom to operate?

Gadofosveset trisodium
is the generic ingredient in one branded drug marketed by Lantheus Medcl and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Gadofosveset trisodium has forty-three patent family members in twenty-six countries and eight supplementary protection certificates in seven countries.

Summary for Generic Name: gadofosveset trisodium

US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Clinical Trials: see list18
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:gadofosveset trisodium at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 2008DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-002Dec 22, 2008DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: gadofosveset trisodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 2008► Subscribe► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-002Dec 22, 2008► Subscribe► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-002Dec 22, 2008► Subscribe► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-002Dec 22, 2008► Subscribe► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 2008► Subscribe► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-002Dec 22, 2008► Subscribe► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 2008► Subscribe► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 2008► Subscribe► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-002Dec 22, 2008► Subscribe► Subscribe
Lantheus Medcl
ABLAVAR
gadofosveset trisodium
SOLUTION;INTRAVENOUS021711-001Dec 22, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: gadofosveset trisodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,011,815Diagnostic imaging contrast agents with extended blood retention► Subscribe
8,394,356Diagnostic imaging contrast agents with extended blood retention► Subscribe
7,229,606Diagnostic imaging contrast agents with extended blood retention► Subscribe
7,060,250Diagnostic imaging contrast agents with extended blood retention► Subscribe
8,017,105Diagnostic imaging contrast agents with extended blood retention► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: gadofosveset trisodium

Country Document Number Estimated Expiration
Netherlands300253► Subscribe
South Korea100403755► Subscribe
Hong Kong1078468► Subscribe
China1177806► Subscribe
Norway326114► Subscribe
South Africa9600417► Subscribe
Denmark0806968► Subscribe
Japan2006342181► Subscribe
China101011586► Subscribe
Norway973510► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: GADOFOSVESET TRISODIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0806968/01Switzerland► SubscribeFORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
0253Netherlands► Subscribe300253, 20160116, EXPIRES: 20201002
C 037/2006Ireland► SubscribeSPC 037/2006: 20070528, EXPIRES: 20201002
C0028France► SubscribePRODUCT NAME: GADOFOSVESET TRISODIQUE; REGISTRATION NO/DATE: EU/1/05/313/001-009 20051003
2007 00016Denmark► Subscribe
C/GB07/011United Kingdom► SubscribePRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
2007003Lithuania► SubscribePRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REG NO/DATE: EU/1/05/313/001-009 20051005
2007003,C0806968Lithuania► SubscribePRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REGISTRATION NO/DATE: EU/1/05/313/001, 2005 10 05 EU/1/05/313/002, 2005 10 05 EU/1/05/313/003, 2005 10 05 EU/1/05/313/004, 2005 10 05 EU/1/05/313/005, 2005 10 05 EU/1/05/313/006, 2006 10 05 EU/1/05/313/007, 2005 10 05 EU/1/05/313/008, 2005 10 05 EU/1/05/313/00 2005100
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
McKinsey
Johnson and Johnson
Healthtrust
QuintilesIMS
Daiichi Sankyo
US Department of Justice
Dow
Federal Trade Commission
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot